Che Ismail Che Noh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Che Ismail Che Noh has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Aishath Azna Ali
1 shared publication- Asma Abdullah Nurul
School of Health Sciences, Universiti Sains Malaysia, Kelantan, Malaysia
1 shared publication - Firdaus Hayati
Department of Surgery, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah, Malaysia
1 shared publication - Imran Ahmad
Department of Family Medicine, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
1 shared publication M. Shamsur Rahman
Department of Biomedical Sciences and Therapeutics, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Sabah
1 shared publicationMarjmin Osman
1 shared publication
Latest Publications
- Open Access
- 30 August 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (9) , 1115
Cytokine (IL-10, IL-6, TNF-α and TGF-β1) Gene Polymorphisms in Chronic Hepatitis C Virus Infection among Malay Male Drug Abusers
Cytokines play an important role in modulating inflammation during viral infection, including hepatitis C virus (HCV) infection. Genetic polymorphisms of cytokines can alter the immune response against this infection. The objective of this study was to investigate the possible association between chronic hepatitis C virus infection susceptibility and cytokine gene polymorphism for interleukin-10 (IL-10) rs1800896 and rs1800871, interleukin 6 (IL-6) rs1800795, TNF-α rs1800629, and TGF-β1 rs1800471 in Malay male drug abusers. The study was conducted on 76 HCV-positive (HP) male drug abusers and 40 controls (HCV-negative male drug abusers). We found that there were significant differences in the frequencies of genotype for IL-10 rs1800871 (p = 0.0386) and at the allelic level for IL-10 rs1800896 A versus G allele (p = 0.0142) between the HP group and the control group. However, there were no significant differences in gene polymorphism in interleukin 6 rs1800795, TNF-α rs1800629 and TGF-β1 rs1800471. These findings suggest significant associations between gene polymorphism for IL-10 rs1800871, IL-10 rs1800896 (at the allelic level) and susceptibility to HCV infection among Malay male drug abusers.
- 30 August 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (9) , 1115
Open AccessCytokine (IL-10, IL-6, TNF-α and TGF-β1) Gene Polymorphisms in Chronic Hepatitis C Virus Infection among Malay Male Drug Abusers
Cytokines play an important role in modulating inflammation during viral infection, including hepatitis C virus (HCV) infection. Genetic polymorphisms of cytokines can alter the immune response against this infection. The objective of this study was to investigate the possible association between chronic hepatitis C virus infection susceptibility and cytokine gene polymorphism for interleukin-10 (IL-10) rs1800896 and rs1800871, interleukin 6 (IL-6) rs1800795, TNF-α rs1800629, and TGF-β1 rs1800471 in Malay male drug abusers. The study was conducted on 76 HCV-positive (HP) male drug abusers and 40 controls (HCV-negative male drug abusers). We found that there were significant differences in the frequencies of genotype for IL-10 rs1800871 (p = 0.0386) and at the allelic level for IL-10 rs1800896 A versus G allele (p = 0.0142) between the HP group and the control group. However, there were no significant differences in gene polymorphism in interleukin 6 rs1800795, TNF-α rs1800629 and TGF-β1 rs1800471. These findings suggest significant associations between gene polymorphism for IL-10 rs1800871, IL-10 rs1800896 (at the allelic level) and susceptibility to HCV infection among Malay male drug abusers.
- Open Access
- 1 January 2018
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Case Reports
- Vol. 26 (2) , 102-104
Cystic Biliary Atresia: A Delayed Diagnosis of Obstructive Jaundice
Cystic biliary atresia is an uncommon variant of biliary atresia. It is the most usual cause of neonatal jaundice which requires surgical intervention and liver transplantation in children. Herein, we present a case of a 2-month-old baby with persistent obstructive jaundice, who was not properly investigated prior to this. After the diagnosis has been established, we proceeded with the Kasai-type portoenterostomy. Even slightly delayed, the patient recovered well postoperatively and subsequently jaundice resolved.
- 1 January 2018
- Published by Turkiye Klinikleri in Turkiye Klinikleri Journal of Case Reports
- Vol. 26 (2) , 102-104
Open AccessCystic Biliary Atresia: A Delayed Diagnosis of Obstructive Jaundice
Cystic biliary atresia is an uncommon variant of biliary atresia. It is the most usual cause of neonatal jaundice which requires surgical intervention and liver transplantation in children. Herein, we present a case of a 2-month-old baby with persistent obstructive jaundice, who was not properly investigated prior to this. After the diagnosis has been established, we proceeded with the Kasai-type portoenterostomy. Even slightly delayed, the patient recovered well postoperatively and subsequently jaundice resolved.
- Open Access
- 12 December 2017
- Published by Universiti Malaysia Sabah (UMS) in Borneo Journal of Medical Sciences (BJMS)
- Vol. 11 (3) , 3-12
Immunotherapy for Treatment of Cancer: A Review
Cancer is the leading cause of morbidity and mortality worldwide and has put heavy burden on public resources. The incidence of cancer and cancer related deaths are both increasing in trend. The conventional treatment for cancer includes surgery, radiation therapy and chemotherapy. However, the use of radiotherapy and chemotherapy, though effective, can be limited for their toxicities. Better understanding of human immunological system has enabled researchers to develop novel immune-based therapeutic agents for cancer. The effectiveness of immunotherapy, either as a single or combination therapy with conventional treatment has been proven through numerous studies. Immunotherapy also has the advantages over radio-chemotherapy for being less toxic, and more target-specific. There are many types of immunotherapies established for treatment of cancer. These include monoclonal antibodies, prophylactic vaccines, immune adjuvants, and cytokines. Beside the existing therapy, various investigational immunotherapy candidates are currently undergoing active development, such as therapeutic cancer vaccines and CAR-T cell therapy, providing better option for treatment of cancer in the near future. Keywords: cancer, immunotherapy, monoclonal antibodies, vaccines, cytokines, chimeric antigen receptors
- 12 December 2017
- Published by Universiti Malaysia Sabah (UMS) in Borneo Journal of Medical Sciences (BJMS)
- Vol. 11 (3) , 3-12
Open AccessImmunotherapy for Treatment of Cancer: A Review
Cancer is the leading cause of morbidity and mortality worldwide and has put heavy burden on public resources. The incidence of cancer and cancer related deaths are both increasing in trend. The conventional treatment for cancer includes surgery, radiation therapy and chemotherapy. However, the use of radiotherapy and chemotherapy, though effective, can be limited for their toxicities. Better understanding of human immunological system has enabled researchers to develop novel immune-based therapeutic agents for cancer. The effectiveness of immunotherapy, either as a single or combination therapy with conventional treatment has been proven through numerous studies. Immunotherapy also has the advantages over radio-chemotherapy for being less toxic, and more target-specific. There are many types of immunotherapies established for treatment of cancer. These include monoclonal antibodies, prophylactic vaccines, immune adjuvants, and cytokines. Beside the existing therapy, various investigational immunotherapy candidates are currently undergoing active development, such as therapeutic cancer vaccines and CAR-T cell therapy, providing better option for treatment of cancer in the near future. Keywords: cancer, immunotherapy, monoclonal antibodies, vaccines, cytokines, chimeric antigen receptors
- 12 December 2017
Immunotherapy for treatment of cancer: a review.